(Q40372445)

19 September 2017

1 reference

title

The role of vanadium in the management of diabetes (English)

1 reference

19 September 2017

Brichard SM

1

1 reference

PubMed ID

7482987

19 September 2017

Henquin JC

series ordinal

2

1 reference

19 September 2017

1 August 1995

1 reference

Trends in Pharmacological Sciences

19 September 2017

1 reference

19 September 2017

16

1 reference

19 September 2017

8

1 reference

19 September 2017

265-270

1 reference

New Pharmacological Approaches to Therapy of NIDDM

19 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989043-4

7 January 2021

Management of non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989043-4

7 January 2021

Effects of vanadium on glucose metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989043-4

7 January 2021

Vanadate inhibits glucose output from isolated perfused rat liver

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989043-4

7 January 2021

Vanadate induces the recruitment of GLUT-4 glucose transporter to the plasma membrane of rat adipocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989043-4

7 January 2021

Stimulatory release of lipoprotein lipase activity from rat fat pads by vanadate

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989043-4

7 January 2021

Selectivity of the insulin-like actions of vanadate on glucose and protein metabolism in skeletal muscle

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989043-4

7 January 2021

Insulin signal transduction pathways.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989043-4

7 January 2021

The insulin-like effect of sodium vanadate on adipocyte glucose transport is mediated at a post-insulin-receptor level

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989043-4

7 January 2021

The insulin-like effect of vanadate on lipolysis in rat adipocytes is not accompanied by an insulin-like effect on tyrosine phosphorylation

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989043-4

7 January 2021

Activation of mitogen activated protein (MAP) kinases by vanadate is independent of insulin receptor autophosphorylation

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989043-4

7 January 2021

Vanadate augments insulin binding and prolongs insulin action in rat adipocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989043-4

7 January 2021

Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989043-4

7 January 2021

Long term improvement of glucose homeostasis by vanadate treatment in diabetic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989043-4

7 January 2021

Toxicity studies on one-year treatment of non-diabetic and streptozotocin-diabetic rats with vanadyl sulphate

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989043-4

7 January 2021

Vanadate treatment rapidly improves glucose transport and activates 6-phosphofructo-1-kinase in diabetic rat intestine

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989043-4

7 January 2021

Vanadate treatment of diabetic rats reverses the impaired expression of genes involved in hepatic glucose metabolism: effects on glycolytic and gluconeogenic enzymes, and on glucose transporter GLUT2

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989043-4

7 January 2021

Vanadate treatment restores the expression of genes for key enzymes in the glucose and ketone bodies metabolism in the liver of diabetic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989043-4

7 January 2021

Oral administration of vanadate to streptozotocin-diabetic rats restores the glucose-induced activation of liver glycogen synthase

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989043-4

7 January 2021

Correction of chronic hyperglycemia with vanadate, but not with phlorizin, normalizes in vivo glycogen repletion and in vitro glycogen synthase activity in diabetic skeletal muscle

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989043-4

7 January 2021

Long-term effectiveness of oral vanadyl sulphate in streptozotocin-diabetic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989043-4

7 January 2021

Tissue-specific correction of lipogenic enzyme gene expression in diabetic rats given vanadate

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989043-4

7 January 2021

Effect of in vivo vanadate treatment on insulin receptor tyrosine kinase activity in partially pancreatectomized diabetic rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989043-4

7 January 2021

Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989043-4

7 January 2021

Long term improvement of glucose homeostasis by vanadate in obese hyperinsulinemic fa/fa rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989043-4

7 January 2021

Effect of cholesterol synthesis inhibition in normocholesteremic young men

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989043-4

7 January 2021

Vanadium, Excretion, toxicity, lipid effect in man

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989043-4

7 January 2021

Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989043-4

7 January 2021

Comparison of the effects of various vanadium salts on glucose homeostasis in streptozotocin-diabetic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989043-4

7 January 2021

Improvement of mild hypoinsulinaemic diabetes in the rat by low non-toxic doses of vanadate

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989043-4

7 January 2021

Acute toxicity of vanadium compounds in rats and mice

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989043-4

7 January 2021

Transformation of cells by an inhibitor of phosphatases acting on phosphotyrosine in proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989043-4

7 January 2021

Glucose-lowering effects of a new organic vanadium complex, bis(maltolato)oxovanadium(IV)

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989043-4

7 January 2021

The protein tyrosine phosphatase inhibitor, pervanadate, is a powerful antidiabetic agent in streptozotocin-treated diabetic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0165-6147%2800%2989043-4

7 January 2021

10.1016/S0165-6147(00)89043-4

Identifiers

DOI

1 reference

19 September 2017

1 reference

PubMed ID

7482987